Glaukos Q2 Earnings Call Highlights
Glaukos (NYSE:GKOS) reported Q2 updates on iDose TR, including acceleration across Medicare Administrative Contractor regions and no material demand pull-forward from proposed LCDs. International glaucoma revenue rose to $36.6M (+17%); corneal health revenue rose 48% to $30.4M with ~$11M Epioxa. Gross margin was ~85%. Full-year targets: gross margin 84% to 86%, corneal health growth ~20%.
How this was made
The 30-second read
Why it matters
Management reiterated full-year gross margin targets and provided specific drivers for mix (iDose TR and Epioxa). The key incremental trading risk is Q3 volatility tied to Epioxa’s shift from Photrexa and a miscellaneous billing code to a permanent product-specific J-code effective July 1.
Market read
Traders get actionable guidance-level details: gross margin target maintained, operating expense outlook provided, and a near-term reimbursement/billing transition flagged as a likely source of Q3 volatility.
What to watch
International FX tailwinds are expected to diminish in 2H, so investors may need to separate currency effects from underlying growth when modeling full-year international revenue.
Background
The piece summarizes Glaukos’ Q2 earnings call, focusing on iDose TR performance, Medicare LCD activity, international glaucoma and corneal franchise trends, and pipeline/profitability updates.
Ticker impact
Glaukos guided 2026 gross margin to 84% to 86% and flagged Q3 volatility from Epioxa J-code transition effective July 1.
Choppy trading risk into and through Q3 as investors weigh transition-related reimbursement friction versus improving gross margin and international growth outlook.
The article provides specific management targets (gross margin range, operating expense outlook) and a concrete operational catalyst (J-code transition July 1) that can affect near-term demand capture and billing behavior.
Market effects
Could influence sentiment toward ophthalmic medtech reimbursement dynamics and MIGS/corneal franchise durability.
International growth outlook is maintained but Germany and Switzerland face reimbursement and competitive trialing headwinds.
CMS proposed 2027 rules and LCD proposals for iDose TR may affect broader US reimbursement expectations for glaucoma therapies.
Counterpoint
If the Epioxa J-code transition issues resolve faster than management expects, the market may over-discount Q3 volatility and re-rate the franchise.
Key entities
- companyGlaukos
NYSE-listed medical technology company focused on glaucoma and corneal therapies, including iDose TR and Epioxa.
- regulatorCMS
US Centers for Medicare and Medicaid Services, referenced for proposed 2027 rules affecting reimbursement for Glaukos procedures.
- productEpioxa
FDA-approved epithelium-on corneal cross-linking therapy for keratoconus, with a permanent J-code effective July 1.
